While AI makes VC faster, it’s not necessarily wiser. In healthcare, where breakthroughs rarely resemble anything the market has seen before, that distinction is everything.
Kurma Partners’ new fund is the venture capital firm’s fourth and largest. Previous Kurma investments have led to exits that include the acquisitions of Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma.
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
The AI Health Fund launched Treehub, a new residency program designed to back and build healthcare AI startups at the earliest stages, often before companies are even formed. It is supported by prominent figures in the Silicon Valley venture capital world, including Tim Draper and Anne Wojcicki.
Sidewinder Therapeutics and Stipple Bio each raised mega-rounds of financing to support their approaches to improving the targeting abilities of antibody drug conjugates for cancer. Both startups are on track to enter the clinic next year.
There are no FDA-approved therapies for GPC3, a protein highly expressed by liver cancers. Oricell Therapeutics claims its cell therapy could be best in this class, but it faces competition from companies such as AstraZeneca and Eureka Therapeutics.
Katie Jacobs Stanton, founder of Moxxie Ventures, shared some details of how she and her team evaluate healthcare AI startups. She stressed the need for founders with deep industry expertise, differentiated products and realistic distribution strategies.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Vima Therapeutics is expanding to Parkinson’s disease following early clinical results showed proof of concept for its drug in isolated dystonia, a rare neurological movement disorder. The startup says its drug could address the biology underpinning many movement disorders.
Nitra announced that it raised $187 million in the past six months. The AI-powered platform — which is now used by more than 700 clinics — manages payments, procurement, inventory, scheduling and insurance verification in a single platform.
The Series B extension brings Atavistik Bio’s Series B financing to $160 million. The startup’s lead program is in development for hereditary hemorrhagic telangiectasia (HHT), an inherited bleeding disorder.
Slate Medicines’ antibody drug is designed to block PACAP, a protein associated with migraines. The Phase 1-ready asset was licensed from China-based DartsBio Pharmaceuticals.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Korsana Biosciences’ preclinical Alzheimer’s disease drug comes from a platform technology that enables antibodies to cross the blood-brain barrier. Roche and AbbVie have clinical-stage drugs taking a similar approach to Alzheimer’s.
Cancer drugs are always popular biotech investments, but autoimmune disease also figures prominently in the startup financings announced during the annual J.P. Morgan Healthcare Conference this year.
Obesity and diabetes drug R&D partnerships struck in 2025 represented $20.2 billion in total deal value, a new record high, according to a new report from J.P. Morgan. While IPO activity and venture investment trended downward, M&A activity was significantly higher.
Iambic’s latest financing follows the presentation of data for its breast cancer drug during the recent European Society of Medical Oncology conference. Our financing roundup includes capital raised by startups developing novel therapies immunology, metabolic disorders, genetic diseases, and more.
Town Hall Ventures launched its fourth fund, targeting $440 million to back startups using AI to improve healthcare access and outcomes for underserved populations.